You just read:

Asterias Biotherapeutics Announces Data Monitoring Committee Unanimously Recommends Continuation of SCiStar Phase 1/2a Clinical Trial of AST-OPC1 for Cervical Spinal Cord Injury

News provided by

Asterias Biotherapeutics, Inc.

Apr 25, 2017, 07:00 ET